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Abstract
Objectives Human papillomavirus (HPV) is a sexually
transmitted infection of particular interest because of its
high prevalence rate and strong causal association with
cervical cancer. Two prophylactic vaccines have been
developed and different countries have made or will soon
make recommendations for the vaccination of girls. Even if
there is a consensus to recommend a vaccination before the
beginning of sexual activity, there are, however, large
discrepancies between countries concerning the perceived
usefulness of a catch-up procedure and of boosters. The
main objective of this article is to simulate the impact on
different vaccination policies upon the mid- and long-term
HPV 16/18 age-specific infection rates.
Methods We developed an epidemiological model based
on the susceptible–infective–recovered approach using
Swiss data. The mid- and long-term impact of different
vaccination scenarios was then compared.
Results The generalization of a catch-up procedure is
always beneficial, whatever its extent. Moreover, pending
on the length of the protection offered by the vaccine,
boosters will also be very useful.
Conclusions To be really effective, a vaccination cam-
paign against HPV infection should at least include a catch-
up to early reach a drop in HPV 16/18 prevalence, and
maybe boosters. Otherwise, the protection insured for
women in their 20s could be lower than expected, resulting
in higher risks to later develop cervical cancer.
Keywords Human papillomavirus  Vaccination 
Catch-up  Booster  Epidemiological model  SIR model
Introduction
Human papillomavirus (HPV) is a sexually transmitted
virus of particular interest, because of its high prevalence
rate, and because of the causal association of the high risk
(HR) HPV types, most often types 16 and 18, with cervical
cancer (Bosch et al. 2002; Brown et al. 2005; IARC
Monograph Working Group 2007). HPV infection is very
common in sexually active adolescents and young adults
(Dunne and Markowitz 2006; Wiley and Masongsong
2006), and the acquisition of HPV occurs soon after sexual
debut (Brown et al. 2005; Centers for Disease Control and
Prevention 2007) as sexual intercourse is the primary route
of genital HPV infection (Burchell et al. 2006). More than
100 different HPV types have been identified, the most
problematic ones being types 16 and 18. Women under age
25 years have the highest acquisition of HR HPV types per
year (Bosch and Harper 2006). Swiss data based on a small
clinical sample (N = 134) of adolescents aged 14–20 years
show a prevalence of 14.2% for HR HPV type (Lu¨dicke
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et al. 2001). A US-based study among women aged 18–
25 years showed an overall prevalence of 27% that
declined with age (Manhart et al. 2006). In the United
Kingdom, HPV prevalence rates decline from 19% for
those under age 25 to less than 3% for those aged 40 and
above (Peto et al. 2004).
Much attention has been recently ported to HPV, since
two prophylactic vaccines (Cervarix and Gardasil) have
proven to be well-tolerated, highly immunogenic, and
effective in preventing type specific cervical HPV infection
and associated intraepithelial neoplasia (Lowy and Schiller
2006). Both vaccines prevent HPV16 and 18 infections
when three intramuscular doses are administered over
6 months to young adults. It must be noted that since all
trials were performed among women aged 18 and over,
protection in younger girls is only an extrapolation. Even if
there is a consensus to recommend a vaccination before the
beginning of sexual activity, there are, however, large
discrepancies between countries with respect to the target
ages for basic and catch-up vaccination. The need for
boosters will also rely on the results of still ongoing phase
III and IV trials. The purpose of this article is then to
explore and compare different vaccination scenarios.
Sexual behavior is the most constant predictor of
acquiring HPV infection (Centers for Disease Control and
Prevention 2007). Although many risk factors have been
described in the literature, number of sexual partners
(Lu¨dicke et al. 2001; Moscicki et al. 2001; Tarkowski et al.
2004; Dunne and Markowitz 2006; Manhart et al. 2006;
Dunne et al. 2007), together with having had a new sex
partner (Giuliano et al. 2002; Winer et al. 2003; Dunne and
Markowitz 2006; Dunne et al. 2007) are the most consis-
tent. Other factors such as younger age (Ho et al. 1998;
Dunne and Markowitz 2006; Manhart et al. 2006; Dunne
et al. 2007), early age at first intercourse (Kahn et al. 2002;
Manhart et al. 2006), or substance use have also been
described as risk factors, but other studies found no asso-
ciation with them (Ho et al. 1998; Kjaer et al. 2001;
Lu¨dicke et al. 2001; Kahn et al. 2002; Sellors et al. 2003;
Winer et al. 2003; Tarkowski et al. 2004; Burchell et al.
2006; Manhart et al. 2006). The characteristics of the
sexual partner’s behavior are also important. It has been
described that partner’s promiscuity (defined as number of
sexual partners) is the most important risk factor (Ho et al.
1998; Kahn et al. 2002; Winer et al. 2003; Dunne and
Markowitz 2006; Winer et al. 2006).
HPV transmission is directly linked to the sexual
behavior of adolescents and young adults. In Switzerland,
median age at first intercourse is 18.5 years both for males
and females, and the proportion of those having had sexual
intercourse before age 15 is 6.8% for males and 3.4% for
females (Wellings et al. 2006). The rate of sexual activity
(intercourse) among Swiss youth ranges from 13% of
males and 7% of females at age 14 to 80% for both genders
at age 20 (Kuendig et al. 2003; Narring et al. 2004). Swiss
data also indicate that 36.6% of males aged 17–20 had one
partner in the previous year, 18% two, and 12% three or
more. The percentages for females in the same age group
were, respectively, 48, 10, and 5%. For males aged 21–
30 years, 63% had one partner in the previous year, 10%
two and 14% three or more. For females in this age group,
the percentages were 85, 5, and 4%. Finally, 85% of males
aged 31–45 had one partner in the previous year, 5% two
and 6% three, while for females the figures were 89, 3, and
1% (Balthasar et al. 2003).
As for any new vaccine, the duration of the vaccine’s
protection is yet undefined (Centers for Disease Control
and Prevention 2007), but results available to date only
demonstrate a sustained efficacy up to 4.5/6 years (Dunne
and Markowitz 2006; Ault 2007; Centers for Disease
Control and Prevention 2007). Consequently, the potential
need for a booster is a research area of greatest importance
(Bosch and Harper 2006). Moreover, if a booster is
required, focusing vaccination programs on 12-year-olds
may be more cost-effective than focusing on infants (Taira
et al. 2004).
It has also been debated whether males should be vac-
cinated. Although some authors (Hugues et al. 2002) report
that vaccinating both men and women would result in a
higher decrease in HPV prevalence, modeling evidence to
date indicates that vaccinating both genders would have
little benefit over vaccinating females only (Barnabas et al.
2006).
This article follows from a request made by the Swiss
Commission for Vaccination to perform a modeling of the
impact of a vaccine upon the infection rate by HR HPV
types among Swiss females. Here, we compare the mid-
and long-term efficacy of the different combinations of
catch-up and/or boosters on the basis of an epidemiological
model of the HPV infection prevalence estimated from
Swiss data. In all cases, the routine vaccination program
would start at age 12.
Methods
Our model of HPV virus diffusion is derived from the
classic susceptible–infective–recovered (SIR) model
introduced first by Kermack and McKendrick (1927) and
then broadly used in epidemiology (Anderson 1982; Daley
and Gani 2001). A similar, but less complete, HPV model
was proposed by Corley (2006); other approaches are due
to French et al. (2007) and Insinga et al. (2007). SIR
models describe year after year a cohort of individuals
mimicking a real population. Individuals in the model are
classified as either susceptible of being infected (state S),
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infective (state I), or recovered (state R). Two additional
states, V for vaccinated and VI for vaccinated–infective are
also considered to take into account the effect of a vacci-
nation program. State V groups individuals that are
immune after having received the vaccine. State VI groups
individuals having received the vaccine when already
infected. For the purpose of clarity, the rare individuals
belonging to this last state are aggregated with infective
when presenting the results. The model considers individ-
uals of both genders, but only results for females are
reported.
The level of sexual activity depends on the individuals
and must be taken into account into the modeling. For that
purpose, the population was divided into several mutually
exclusive sexual profiles corresponding to different groups
of sexual activity. The repartition among groups was spe-
cific for each class of age. Each group is defined by the
average number of different partnerships formed each year.
The core of any model for sexually transmitted viruses is a
process of sexual mixing between individuals (Aral et al.
1999). This process manages all sexual contacts made
between individuals, hence all possibilities of virus trans-
mission. The process of sexual mixing used in this model is
derived from the one proposed by Garnett (2002). On the
contrary of the solution adopted in previous models, the
process implemented here takes explicitly into account the
fact that partnerships between individuals of different ages
are very frequent.
The model works in discrete time, each period being
1 year. The transitions from any state of the model (S, I,
R, V, and VI) to any other state are modeled through a
set of difference equations. Figure 1 shows the possible
transitions. Before vaccination occurs, only states S, I,
and R are possible. When vaccination occurs, states V
and VI become active. In most cases, individuals become
vaccinated either from the susceptible or recovered states,
but they can also come from the infective state if they
clear infection the same year they are vaccinated. Indi-
viduals can become vaccinated–infective (VI) if they are
vaccinated when staying infected, or if they are suscep-
tible and get an infection the same year they are
vaccinated. After vaccination, individuals can stay in the
vaccinated and vaccinated–infective states, but they can
also leave these states to become susceptible, infective,
or recovered. Vaccinated individuals become susceptible
again when the immunity provided by the vaccine van-
ishes, and they become infective when they lose their
immunity at the same time they get infected. Finally,
they can also become vaccinated–infective if they get
infected when keeping the immunity provided by the
vaccine, but this very particular situation can occur only
if the vaccine does not provide 100% protection. Vac-
cinated–infective individuals become simply infective if
the immunity provided by the vaccine vanishes, and they
enter in the recovered state if they clear the infection at
the same time. An even more complex situation occurs at
the exact time a booster is administered. This complexity
comes from different reasons: not all individuals will
receive the booster; simultaneously to receiving the
booster, an individual can also become infected, or clear
an infection; a significant proportion of the population
can be still protected by the vaccine. Finally, the years
following a booster, transitions follow again the schema
given in Fig. 1c.
Table 1 describes the main parameters of the model and
gives their values as estimated for Switzerland from the
literature. A more detailed description of all parameters is
provided in Suris et al. (2007). There are 20 profiles of
sexual activity, each of them grouping 5% of the total
population of a particular age. Each profile corresponds to
a different group of population and is defined as the
average number of sexual partners per year. Such a large
number of profiles is not mandatory, but it was the best
choice given available Swiss data. For each profile and
each class of age, the average number of sexual partner-
ships formed by year was computed from Swiss data. For
instance, the first profile indicates total abstinence, what-
ever the age class; the ninth profile corresponds to an
average of 1 sexual partner per year between ages 17 and
60, and no partner before or after that; the last profile
corresponds to an average of 2 sexual partners per year
between ages 11 and 14, 9 partners between 15 and 16, 7
partners between 17 and 20, and 3 partners between 21 and
80. The parameter of sexual mixing is the probability that a
sexual partnership is formed with someone belonging to a
At vaccination age 
(b)
  Before vaccination 
(a)
   At booster age 
(d)
 After  vaccination 
(c)
Fig. 1 Possible transitions at different times between the five states
considered in the model: susceptible of being infected (S), already
infective (I), having recovered from the infection (R), vaccinated (V),
and vaccinated when being infective (I). The arrows indicate the
possible transitions between the five states
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different sexual profile. This parameter takes a high value
of 0.8 (maximum 1) reflecting the fact that with no less
than 20 different profiles of sexual activity, it is likely that
the majority of the sexual partnerships are formed with
individuals belonging to another profile.
The vaccination coverage has been fixed to 85%
(female) and 0% (male). The latter case is a consequence of
the choice of not exploring male vaccination. Since no data
exist at the time for HPV, the vaccination rate for females
has been derived from the one for Hepatitis B. In Swit-
zerland this rate is still low (63% in 2006) since
vaccination is not mandatory in all cantons, so we used
data from other European countries (Italy: 92%, Germany:
84%, and Austria: 92%) as provided by the World Health
Organization (2007).
At the beginning of the simulation, an initial population
is created. Each subsequent year of the simulation consists
then in the following steps:
Table 1 Main parameters of the HPV model
Parameter Estimation Main source for estimation
Number of age classes 9 Specific
Age classes 1–10, 11–14, 15–16, 17–20, 21–
30, 31–45, 46–60, 61–80, 81–
100
Chosen in regard of available data
Number of sexual activity profiles 20 Specific
Survival probability for individual of each age, by
sex
Available upon request Swiss Statistics
Initial proportion of the population being infected by
the HPV virus, by age, sex and sexual activity
profile
Available upon request Endemic values computed from the reference
scenario without vaccination program
Age at vaccination 12 Taira et al. (2004)
Percentage of individuals being vaccinated, by sex Female: 85%, male: 0% For females: Average from the Hepatitis B
vaccination rate in various European
countries
Age(s) of the booster(s) 5 years after vaccination, or 5 and
10 years after vaccination in the
case of two boosters
Our analysis is based on the assumption that
the period of full efficacy of the vaccine is
5 years, so the booster must be
administered at the end of this period
Percentage of individuals receiving a booster, by sex Female: 85%, male: 0% See vaccination rate
Length in years of the total immunity provided by
the vaccine and/or the booster(s)
Variable Clifford et al. (2005), Dunne and Markowitz
(2006)
Catch-up procedure (yes or no) Variable –
Maximal age to receive the catch-up Variable ACIP (2007), Saslow et al. (2007)
Percentage of individuals receiving the catch-up, by
sex
Female: 85%, male: 0% See vaccination rate
Proportion of vaccinated individuals losing their
immunity by years during the period of total
immunity, and then after this period
0%, then 10% Koutsky and Harper (2006)
Average number of sexual partnerships formed by
year, for each sexual activity profile and each age
class
Available upon request Narring et al. (2004); Balthasar et al. (2003)
Proportion of the population forming sexual
partnerships with individuals belonging to other
profiles of sexual activity
0.8 Specific
Transmission rate of the virus from one sex to
another
Female to male: 75%, male to
female: 75%
Hugues et al. (2002)
Proportion of infective individuals entering in
remission each year
70% Centers for Disease Control and Prevention
(2007)
Proportion of remission individuals becoming
susceptible again each year
0.5 Specific
We describe here the main parameters of the simulation model, and we provide their values as estimated for Switzerland from the literature.
‘‘Specific’’ indicates that the value has been chosen specifically in regard of the availability of Swiss data. ‘‘Variable’’ indicates that the parameter
varies in function of the vaccination scenario
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1. The sexual mixing between the different groups of
population is computed. This mixing takes into account
the proportion of sexual contacts occurring between
each couple of sexual activity profiles, and the average
number of partnerships per age class and sexual profile.
2. A new repartition of the population between the five
states is computed using a set of difference equations
and the final situation of the previous year. For
instance, considering the situation of Fig. 1a, we have
three equations giving the number of individuals
belonging to states S, I, and R at time t ? 1 in
function of the number of individuals in these same
states at time t:
Stþ1 ¼ St  astIt þ dRt ð1Þ
Rtþ1 ¼ Rt þ bIt  dRt ¼ ð1  dÞRt þ bIt ð2Þ
Itþ1 ¼ It þ astIt  bIt ¼ 1 þ ast  bð ÞIt ð3Þ
The parameter a is the average number of infections that
could be caused by an infective individual during one
period. Since only susceptible individuals can become
infective, the number of new infective at time t ? 1 is
given by astIt, where st is the proportion of susceptible
individuals in the population at time t. After a certain
time, infective individuals recover, and we note b the
proportion of individuals doing so each period. Finally,
d is the proportion of recovering individuals becoming
susceptible again each time period. Equation 1 tells that
the number of susceptible individuals at time t ? 1 is
equal to the number of susceptible individuals at time t
minus the number of susceptible individuals infected
between t and t ? 1, plus the number of recovering
individuals becoming susceptible again between t and
t ? 1. Equation 2 tells that the number of recovering
individuals at time t ? 1 is equal to the number of
individuals already recovering at time t plus the number
of infective individuals recovering between t and t ? 1,
minus the number of recovering individuals becoming
susceptible again between t and t ? 1. Finally, Eq. 3
tells that the number of infective individuals at time
t ? 1 is equal to the number of infective individuals at
time t plus the number of individuals infected between t
and t ? 1, less the number of individuals having
recovered between t and t ? 1.
3. Results are adjusted according to the Swiss mortality
table to respect the real age repartition of the
population.
If a vaccination program is implemented at the begin-
ning of the simulation, the impact of this program can be
analyzed after any given number of years. The equilibrium
of the epidemiological model provides the endemic
repartition of the population between the five states.
Based on the recommendations of several countries, we
considered the vaccination of 12 years old girls. Four
scenarios were then compared regarding the efficacy of the
vaccine:
1. Full efficacy of the vaccine during 5 years, no booster.
2. Full efficacy of the vaccine during 5 years, two
boosters after 5 and 10 years.
3. Full efficacy of the vaccine during 10 years, no
booster.
4. Lifelong full efficacy of the vaccine.
Two additional scenarios (full efficacy during 5 years,
one booster after 5 years; full efficacy during 10 years, one
booster after 10 years) were also considered, but we did not
report results here. The first of these scenarios is always
very close to the 10 years/no booster scenario. The second
scenario behave like an intermediary situation between the
10 years/no booster and the 5 years/2 boosters scenarios
after 15 years of vaccination, and it becomes very close to
the lifelong efficacy scenario when considering the ende-
mic situation.
Three catch-up possibilities were also studied:
A. No catch-up.
B. Catch-up up to 18 years.
C. Catch-up up to 25 years.
Our results are reported in terms of proportion of
infected girls by HPV 16/18 types by age. For each type of
catch-up, we compared the vaccination scenarios 15 years
after the beginning of the vaccination campaign. We also
report the long-term endemic situation.
The model has been developed using Matlab 7 (2004).
Stata 9 (2007) has been used for additional statistical
computations.
Results
Figure 2 reports the infection rate by age for females in
Switzerland, both for all HPV types and for HPV 16/18
only. These are the endemic rates estimated from the model
in the absence of vaccination.
The first simulation does not consider any form of catch-
up. Figure 3 reports the expected infection rate by age for
HPV types 16/18, 15 years after the beginning of the
vaccination campaign. Using a 5-year efficacy vaccine the
infection rate would remain below 1% up to age 18, below
2% up to age 22, and below 4% up to age 30. By adding
two boosters, the rate would remain below 1% up to age 25
and under 4% up to age 30. A 10-year efficacy vaccine
would maintain the infection rate under 1% up to age 22,
slightly over 1% at age 25, and below 4% at age 30. A
lifelong efficacy vaccine would follow a very similar curve.
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In all cases, from age 35 onwards, the rates are as low (2%
infected) as if no vaccination was administered.
The second simulation adds a catch-up up to age 18.
Figure 4 reports the expected infection rate by age for HPV
types 16/18, 15 years after the beginning of the vaccination
campaign. In this situation, a 5-year efficacy vaccine would
maintain the infection rate under 1% up to age 20 and
below 2.5% up to age 35. By adding two boosters, the rate
would stay below 1% up to age 30 and below 2% up to age
35. A 10 year efficacy vaccine would keep the rate below
1% up to age 25 and below 2% up to age 35. By using a
lifelong efficacy vaccine, the scenario would be very close
to the 5-years/2 boosters case. In all cases, the infection
rate would be similar to non-vaccination from age 40
onwards.
The third simulation extends catch-up up to age 25.
Figure 5 reports the expected infection rate by age for HPV
types 16/18, 15 years after the beginning of the vaccination
campaign. A 5-year efficacy vaccine without booster would
result in an infection rate below 1% up to age 20 and below
2% up to age 40. For all other cases, the rate would be
maintained below 1% up to age 37.
The last simulation reports the endemic situation in the
absence of any form of catch-up, that is the equilibrium
situation which would be reached at 50 and subsequent
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Fig. 2 HPV infection rate
among Swiss females such as
estimated by the




















Efficacy 5 y / no booster Efficacy 5 y / 2 boosters
Efficacy 10 y / no booster Efficacy lifelong
Fig. 3 Estimated HPV 16/18
infection rate for females by
age. The vaccination targets
12 years old girls with 85%
coverage. No catch-up.
Situation 15 years after the


















Efficacy 5 y / no booster Efficacy 5 y / 2 boosters
Efficacy 10 y / no booster Efficacy lifelong
Fig. 4 Estimated HPV 16/18
infection rate for females by
age. The vaccination targets
12 years old girls with 85%
coverage. Catch-up up to
18 years. Situation 15 years
after the beginning of the
vaccination campaign
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Figure 6 reports the infection rate for HPV types 16 and 18
by age. Using a 5-year efficacy vaccine without booster,
the infection rate would remain below 0.2% up to age 20
and below 0.5% up to age 35. All other scenarios would
prove even more efficient. After 35 years of age, the
infection rate would slowly go up for all scenarios, except
for the lifelong efficacy scenario for which the infection
rate would stay null. Endemic situations with a catch-up up
to 18 or 25 years are virtually identical to the endemic
situation without catch-up, so we did not report the results.
Discussion
Results can be analyzed from two points of view: consid-
ering first the long-term endemic situation many years after
the introduction of the vaccination, it appears clearly that
whatever the duration of the protection offered by the
vaccine, the administration of boosters or the introduction
of a catch-up procedure, the HPV 16/18 infection rate will
be dramatically decreased compared to the default situation
without any vaccination. Even in the lowest vaccination
scenario (5 years efficacy without booster or catch-up), the
infection rate will stay below 0.5% up to 35 years of age,
when the same rate would be higher than 9% by age 18
without vaccination. However, this optimistic view has to
be moderated by the fact that such an endemic situation can
be reached in the most favorable case only 50 years after
the beginning of the vaccination campaign. In the mean-
time, as indicated by results after 15 years of vaccination,
the infection rate will stay non-negligible, emphasizing the
need for an optimal vaccination scenario.
Looking now at the mid-term impact of the vaccina-
tion, three elements are to be considered: the duration of
the full efficacy of the vaccine, the use of boosters, and
the catch-up procedure. At the present time, we expect
that vaccine efficacy may last for decades as HPV vaccine
elicit immune memory and this memory is readily reac-
tivated by a booster dose. However, we are still unsure
whether such booster doses will be needed and if so at
which intervals, so we can here only speculate. Not sur-
prisingly, the longer the full efficacy of the vaccine, the
smaller the infection rate by age. The use of one or two
boosters, if required to sustain the full efficacy of the
vaccine, clearly improves the vaccination plan. Finally,
any catch-up is better than no catch-up at all. However,
our model indicates that the improvement provided by a
catch-up up to age 18 compared to no catch-up at all is
much more important than the improvement provided by a
catch-up up to 25 compared to a catch-up up to 18.
Additional unreported results also show that a catch-up up

















Efficacy 5 y / no booster Efficacy 5 y / 2 boosters
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Fig. 5 Estimated HPV 16/18
infection rate for females by
age. The vaccination targets
12 years old girls with 85%
coverage. Catch-up up to
25 years. Situation 15 years



















Efficacy 5 y / no booster Efficacy 5 y / 2 boosters
Efficacy 10 y / no booster Efficacy lifelong
Fig. 6 Estimated HPV 16/18
infection rate for females by
age. The vaccination targets
12 years old girls with 85%
coverage. No catch-up.
Endemic situation
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to age 22 or 25 provide also similar results, although the
later would result in better coverage and infection rates
than the former. This statement is independent of the
efficacy of the vaccine and of whether or not a booster is
implemented.
This study presents several limitations. First of all, the
model was intended for the case of Switzerland, but data
for estimating the model were very scarce. In fact, the only
prevalence of HPV infection we have found for Switzer-
land is among a small (N = 134) clinical sample of
adolescents in Geneva (Lu¨dicke et al. 2001). As a result,
we have been forced to rely on data from other countries,
mainly the United States. Nevertheless, this fact should not
influence much our results, since there are no reasons to
believe that the situation regarding HPV in Switzerland
differs significantly from the situation in other western
developed countries. Moreover, the use of data from dif-
ferent countries contributes to make the model more
universal.
We chose to build an epidemiological model allowing
transitions from any state to any other state. It could be
argued that some of these transitions should not have been
included, for instance the transition from recovered to
vaccinated, since the vaccine seems to be effective only for
woman naive to the virus. However, this is still an area of
controversy (Hildesheim and Herrero 2007). Moreover, our
model tackles simultaneously HPV types 16 and 18, so we
had to take into account the fact that a woman previously
infected with one of these types could nevertheless obtain
protection against the other one through vaccination.
Finally, such transitions account for only a small number of
all the transitions of the model.
The time step of the model is 1 year. This is maybe too
long, since median time to clearance from HPV infections
has been reported to be less than 1 year (Ho et al. 1998;
Giuliano et al. 2002; Dunne and Markowitz 2006), result-
ing in a distortion of the results. However, the same authors
also reported that clearance time was longer for the HR
HPV types concerned by our study. Moreover, if our model
could potentially find as still infective women which have
already cleared the infection in less than 1 year, this would
be counterbalanced by women found no more infective
after several years by the model.
A more important limitation is the fact that there are not
much data regarding the sexual behavior of Swiss. As an
example, the only data that we have found for the number
of sexual partners (Balthasar et al. 2003) include quite wide
age ranges (17–20, 21–30, and 31–45). We had then to
divide the whole modeled period into only 9 age classes.
This is clearly insufficient, especially after 30 years, the
consequences being a lower reliability of the exact HPV
infection prevalence by age, and too abrupt changes in
prevalence at the limit between age classes.
This paucity of data has not allowed us to fully calibrate
our model. Given these limitations, the model should not
be used to predict the exact prevalence of HPV infection
age by age. However, the model correctly reproduces the
relative change in prevalence due to the implementation of
different vaccination scenarios, so the results are correct in
regard of the objective of the present study.
The model described here focuses only on the effect of
vaccination upon HPV 16 and 18 infection rates. We did
not consider infection by other HPV types, what could limit
the generalization of our results. We also did not consider
the influence of vaccination upon screening policies, nor
the impact of vaccination upon the later development of
cervical cancers. The cost/benefit analysis of the vaccina-
tion is also beyond the scope of the present article. All of
these questions should be addressed through additional
researches.
Based on the preceding analyses, the proposals made to
the Swiss Commission for Vaccination were to implement
a vaccination procedure for all female adolescents between
the age of 12 or 13 and to propose a catch-up procedure up
to at least 18, but preferably 25 years of age. Another
proposal was to envision one (or two) boosters if needed to
insure that females would be protected during the main part
of the period of maximal risk, that is at least up to age 30,
but ideally up to age 35. As the maximal duration of pro-
tection of the vaccine is yet to be determined, whether no,
one or two boosters would be needed remains to be defined
by the long-term follow-up of vaccinated cohorts.
Other factors beyond those appraised by the epidemio-
logical model are also to be considered when choosing an
optimal vaccination plan. First of all, even if no serious
side effects following vaccination have been reported yet
([15 million doses administered), we always lack infor-
mation about possible mid- and long-term side effects
when a new vaccine is introduced. From that point of view,
there is a need to carefully monitor the effects of HPV
vaccination. Given the fact that the odds for developing
any neurological or autoimmune diseases increase with age
(Siegrist et al. 2007), it has to be understood that to vac-
cinate older individuals (after 19 or 20 years of age) entails
an increasing risk for lay people to falsely attribute the
occurrence of illness to the vaccine. Also, the decision
regarding the ideal age range for catch-up procedure must
take into account cost-effectiveness calculation, which
obviously differs from one epidemiological situation to
another. Finally, it must be clear that vaccination cannot
fully replace other prevention tools such as screening and
information campaigns directed toward adolescents and
young adults.
Keeping these considerations in mind, the final recom-
mendation of the Swiss Commission for Vaccination was
to vaccinate all female adolescents aged 11–14 years and
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to propose a catch-up procedure to all females aged 15–
19 years during a 5-year period (Swiss Commission for
Vaccination 2007). The Swiss Commission for Vaccination
recognized the fact that, for sexually active adolescents and
young adults, the advantage of being immunized dimin-
ished as the number of previous sexual partners increased.
The usefulness of HPV vaccination, particularly from age
20, will thus have to be determined on an individual basis.
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